Last reviewed · How we verify
Capecitabine or gemcitabine
Both capecitabine and gemcitabine are nucleoside analogs that inhibit DNA synthesis by interfering with nucleotide metabolism, leading to cancer cell death.
Both capecitabine and gemcitabine are nucleoside analogs that inhibit DNA synthesis by interfering with nucleotide metabolism, leading to cancer cell death. Used for Metastatic colorectal cancer (capecitabine), Metastatic breast cancer (capecitabine), Pancreatic cancer (gemcitabine).
At a glance
| Generic name | Capecitabine or gemcitabine |
|---|---|
| Sponsor | Centre Hospitalier Universitaire Dijon |
| Drug class | Antimetabolite chemotherapy agents |
| Target | Thymidylate synthase (capecitabine); Ribonucleotide reductase and DNA polymerase (gemcitabine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Capecitabine is a prodrug converted to 5-fluorouracil (5-FU) in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA/RNA. Gemcitabine is a deoxycytidine analog that inhibits ribonucleotide reductase and DNA polymerase, causing chain termination. Both are antimetabolite chemotherapy agents used in various solid tumors.
Approved indications
- Metastatic colorectal cancer (capecitabine)
- Metastatic breast cancer (capecitabine)
- Pancreatic cancer (gemcitabine)
- Non-small cell lung cancer (gemcitabine)
- Bladder cancer (gemcitabine)
Common side effects
- Hand-foot syndrome (palmar-plantar erythrodysesthesia)
- Diarrhea
- Nausea and vomiting
- Myelosuppression (neutropenia, thrombocytopenia)
- Fatigue
- Mucositis
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) (PHASE2, PHASE3)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer (PHASE1)
- A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT) (PHASE2)
- YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer (PHASE3)
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capecitabine or gemcitabine CI brief — competitive landscape report
- Capecitabine or gemcitabine updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Dijon portfolio CI